60 Degrees Pharmaceuticals, Inc. (SXTP) 10-Year Financial Performance & Capital Metrics

SXTP • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

About60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.Show more

Revenue $608K +139.6%
EBITDA -$10M -91.0%
Net Income -$8M -111.0%
EPS (Diluted) -18.55 -1852.6%
Gross Margin 36.67% +142.1%
EBITDA Margin -1588.48% +20.3%
Operating Margin -1598.97% +21.3%
Net Margin -1308.01% +11.9%
ROE -181.58% -131.4%
ROIC -276% +70.3%
Debt/Equity 0.04 +9.5%
Interest Coverage -1227.87 -54370.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Share count reduced 88.5% through buybacks
✓Trading at only 0.1x book value

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 2 (bottom 2%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-19.4%

TTM135.78%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-1.47%

EPS CAGR

10Y-

5Y-

3Y-

TTM-127.71%

ROCE

10Y Avg-117.74%

5Y Avg-117.74%

3Y Avg-159.43%

Latest-214.68%

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.16B	17.50	21.60	65.15%	42.87%	48.57%	2.64%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	83.24M	2.80	-0.22			-49.37%		0.24
ALGSAligos Therapeutics, Inc.	44.22M	8.26	-0.39	-74.6%	-32.68%	-120.37%
INOInovio Pharmaceuticals, Inc.	108.55M	1.58	-0.40	-73.83%	-592.82%	-115.42%		0.17
BRNSBarinthus Biotherapeutics plc	29.81M	0.73	-0.47	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.3M	1.11	-0.65			-126.11%		0.19
KLRSKalaris Therapeutics Inc	165.7M	8.86	-0.76			-170.84%

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	2.18M	1.16M	223.21K	253.57K	607.57K
Revenue Growth %	-	-0.47%	-0.81%	0.14%	1.4%
Cost of Goods Sold+	702.99K	850.74K	432.37K	474.55K	384.76K
COGS % of Revenue	0.32%	0.73%	1.94%	1.87%	0.63%
Gross Profit+	1.48M	309.6K	-209.16K	-220.98K	222.81K
Gross Margin %	0.68%	0.27%	-0.94%	-0.87%	0.37%
Gross Profit Growth %	-	-0.79%	-1.68%	-0.06%	2.01%
Operating Expenses+	1.9M	1.43M	1.54M	4.93M	9.94M
OpEx % of Revenue	0.87%	1.24%	6.91%	19.46%	16.36%
Selling, General & Admin	1.46M	1.12M	1.3M	4.24M	5.02M
SG&A % of Revenue	0.67%	0.96%	5.84%	16.73%	8.27%
Research & Development	806.68K	5.51M	525.56K	691.77K	4.99M
R&D % of Revenue	0.37%	4.75%	2.35%	2.73%	8.21%
Other Operating Expenses	-368.11K	-5.19M	-288K	0	-73.77K
Operating Income+	-418.13K	-1.12M	-1.75M	-5.15M	-9.71M
Operating Margin %	-0.19%	-0.97%	-7.84%	-20.33%	-15.99%
Operating Income Growth %	-	-1.69%	-0.56%	-1.94%	-0.88%
EBITDA+	-390.26K	-1.05M	-1.67M	-5.05M	-9.65M
EBITDA Margin %	-0.18%	-0.91%	-7.49%	-19.93%	-15.88%
EBITDA Growth %	-	-1.7%	-0.59%	-2.02%	-0.91%
D&A (Non-Cash Add-back)	27.86K	71.78K	78.79K	100.37K	63.74K
EBIT	-369.04K	-1.09M	-2.19M	-1.53M	-7.95M
Net Interest Income+	-2.68M	-3.17M	-3.99M	-2.29M	-7.91K
Interest Income	0	0	0	0	0
Interest Expense	2.68M	3.17M	3.99M	2.29M	7.91K
Other Income/Expense	-2.63M	-3.14M	-4.43M	1.34M	1.76M
Pretax Income+	-3.05M	-4.26M	-6.18M	-3.81M	-7.96M
Pretax Margin %	-1.4%	-3.67%	-27.68%	-15.04%	-13.09%
Income Tax+	1K	1K	500	250	250
Effective Tax Rate %	1%	1%	1%	0.99%	1%
Net Income+	-3.03M	-4.25M	-6.18M	-3.77M	-7.95M
Net Margin %	-1.39%	-3.66%	-27.69%	-14.85%	-13.08%
Net Income Growth %	-	-0.4%	-0.45%	0.39%	-1.11%
Net Income (Continuing)	-3.05M	-4.26M	-6.18M	-3.81M	-7.96M
Discontinued Operations	0	0	0	0	0
Minority Interest	-569.29K	-576.26K	-572.32K	-72.04K	-80.59K
EPS (Diluted)+	-0.52	-0.74	-1.07	-0.95	-18.55
EPS Growth %	-	-0.42%	-0.45%	0.11%	-18.53%
EPS (Basic)	-0.52	-0.74	-1.07	-0.95	-18.55
Diluted Shares Outstanding	5.78M	5.78M	5.78M	3.96M	454.58K
Basic Shares Outstanding	5.78M	5.78M	5.78M	3.96M	454.58K
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.44M	1.18M	1.1M	7.24M	5.39M
Cash & Short-Term Investments	191.7K	115.4K	264.87K	2.14M	3.39M
Cash Only	191.7K	115.4K	264.87K	2.14M	1.66M
Short-Term Investments	0	0	0	0	1.73M
Accounts Receivable	859.42K	146.36K	45.97K	231.33K	486.75K
Days Sales Outstanding	143.8	46.04	75.16	332.99	292.41
Inventory	1.04M	689.04K	518.58K	466.17K	442.76K
Days Inventory Outstanding	539.77	295.62	437.78	358.55	420.02
Other Current Assets	352.16K	0	68.63K	2.73M	1.07M
Total Non-Current Assets+	163.18K	216.85K	198.2K	541.18K	373.07K
Property, Plant & Equipment	73.41K	107.61K	33.95K	71.28K	149.81K
Fixed Asset Turnover	29.72x	10.78x	6.58x	3.56x	4.06x
Goodwill	0	0	0	0	0
Intangible Assets	80.23K	109.24K	164.25K	227.26K	157.08K
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	9.55K	0	0	242.65K	66.18K
Total Assets+	2.61M	1.39M	1.3M	7.78M	5.76M
Asset Turnover	0.84x	0.83x	0.17x	0.03x	0.11x
Asset Growth %	-	-0.47%	-0.07%	5%	-0.26%
Total Current Liabilities+	1.43M	635.47K	23.92M	2.84M	1.66M
Accounts Payable	1.38M	588.68K	758.67K	506.21K	1.01M
Days Payables Outstanding	714.95	252.56	640.46	389.35	955.86
Short-Term Debt	0	0	21.14M	8.77K	8.77K
Deferred Revenue (Current)	0	0	325K	0	0
Other Current Liabilities	2.04K	0	1.49M	2.31M	640.83K
Current Ratio	1.70x	1.85x	0.05x	2.55x	3.25x
Quick Ratio	0.98x	0.77x	0.02x	2.39x	2.98x
Cash Conversion Cycle	-31.38	89.1	-127.52	302.19	-243.42
Total Non-Current Liabilities+	19.24M	18.91M	1.53M	150.25K	147.12K
Long-Term Debt	15.92M	18.74M	1.27M	150.25K	147.12K
Capital Lease Obligations	0	13K	0	0	0
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	3.22M	0	0	0	0
Total Liabilities	20.68M	19.55M	25.45M	2.99M	1.8M
Total Debt+	15.92M	18.8M	22.42M	172.67K	155.89K
Net Debt	15.73M	18.69M	22.15M	-1.97M	-1.5M
Debt / Equity	-	-	-	0.04x	0.04x
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-0.16x	-0.35x	-0.44x	-2.25x	-1227.87x
Total Equity+	-18.07M	-18.15M	-24.15M	4.8M	3.96M
Equity Growth %	-	-0%	-0.33%	1.2%	-0.18%
Book Value per Share	-3.13	-3.14	-4.18	1.21	8.70
Total Shareholders' Equity	-17.5M	-17.58M	-23.58M	4.87M	4.04M
Common Stock	799.7K	4.98M	239	10	57
Retained Earnings	-18.38M	-22.63M	-28.82M	-32.58M	-40.53M
Treasury Stock	0	0	0	0	0
Accumulated OCI	80.45K	75.83K	73.71K	135.56K	135.47K
Minority Interest	-569.29K	-576.26K	-572.32K	-72.04K	-80.59K

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-167.3K	-649.11K	-1.01M	-4.54M	-5.65M
Operating CF Margin %	-0.08%	-0.56%	-4.52%	-17.92%	-9.3%
Operating CF Growth %	-	-2.88%	-0.56%	-3.5%	-0.24%
Net Income	-3.05M	-4.26M	-6.18M	-3.77M	-7.96M
Depreciation & Amortization	27.86K	71.78K	78.79K	100.37K	63.74K
Stock-Based Compensation	0	0	0	0	3.61M
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	425.74K	642.92K	1.78M	-1.28M	-1.56M
Working Capital Changes	2.43M	2.9M	3.31M	405.36K	192.72K
Change in Receivables	-660.28K	713.06K	100.4K	-185.37K	-255.42K
Change in Inventory	190.78K	312.23K	-52.94K	212.75K	23.41K
Change in Payables	796.29K	-844.67K	169.99K	-214.73K	501.41K
Cash from Investing+	-70.98K	-35.39K	-60.13K	-115.89K	-1.89M
Capital Expenditures	-70.98K	-3.07K	-60.13K	-57.62K	-103.77K
CapEx % of Revenue	0.03%	0%	0.27%	0.23%	0.17%
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	-32.32K	0	-58.27K	-77.34K
Cash from Financing+	277.36K	611.23K	1.22M	6.47M	7.05M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	0	0	116.71K	981.35K	10.96K
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-238.28K	-684.5K	-1.07M	-4.66M	-5.83M
FCF Margin %	-0.11%	-0.59%	-4.79%	-18.37%	-9.59%
FCF Growth %	-	-1.87%	-0.56%	-3.35%	-0.25%
FCF per Share	-0.04	-0.12	-0.19	-1.18	-12.82
FCF Conversion (FCF/Net Income)	0.06x	0.15x	0.16x	1.21x	0.71x
Interest Paid	0	0	2.19K	179.12K	8.77K
Taxes Paid	1.25K	750	1K	1K	2K

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-78.48%	-181.58%
Return on Invested Capital (ROIC)	-	-157.67%	-	-928.58%	-276%
Gross Margin	67.77%	26.68%	-93.71%	-87.15%	36.67%
Net Margin	-139.08%	-366.42%	-2769.49%	-1485.06%	-1308.01%
Debt / Equity	-	-	-	0.04x	0.04x
Interest Coverage	-0.16x	-0.35x	-0.44x	-2.25x	-1227.87x
FCF Conversion	0.06x	0.15x	0.16x	1.21x	0.71x
Revenue Growth	-	-46.81%	-80.76%	13.6%	139.61%

Frequently Asked Questions

Growth & Financials

60 Degrees Pharmaceuticals, Inc. (SXTP) reported $1.0M in revenue for fiscal year 2024. This represents a 56% decrease from $2.2M in 2020.

60 Degrees Pharmaceuticals, Inc. (SXTP) grew revenue by 139.6% over the past year. This is strong growth.

60 Degrees Pharmaceuticals, Inc. (SXTP) reported a net loss of $8.0M for fiscal year 2024.

Dividend & Returns

60 Degrees Pharmaceuticals, Inc. (SXTP) has a return on equity (ROE) of -181.6%. Negative ROE indicates the company is unprofitable.

60 Degrees Pharmaceuticals, Inc. (SXTP) had negative free cash flow of $6.9M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener